Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Pharmaceutical product liability, litigation regimes, and the propensity to patent : an empirical firm-level investigation
ID
Kovač, Mitja
(
Author
),
ID
Datta, Salvini
(
Author
),
ID
Spruk, Rok
(
Author
)
PDF - Presentation file,
Download
(397,39 KB)
MD5: 4E0D8D23E8B7396FC5E360470219204F
URL - Source URL, Visit
https://journals.sagepub.com/doi/10.1177/21582440211009470
Image galllery
Abstract
Do different pharmaceutical product liability regimes in different countries induce propensity to patent? We exploit the variation in pharmaceutical liability and litigation rules across firms in the pharmaceutical industry and countries to explain the firm-level propensity to patent. Drawing on a large dataset from European Patent Office (EPO) covering over 9,950 pharmaceutical patents from 63 countries over the period 1991–2015, we compute the conditional probabilities of individual pharmaceutical firms to acquire a valid-based patent on the validation outcomes and examine whether different liability regimes encourage or deter firm-level propensity to patent. Our empirical strategy addresses firm-level idiosyncrasies, country-level unobserved effects, and common technology shocks that potentially invoke omitted variable bias in the effects of liability regimes on the propensity to patent. Our investigation reveals that liability regimes combined with damage caps, broad statutory excuses, and reversed burden of proof have a strong positive effect on the firm-level patent stock and a negative effect upon EPO patent validation rate. The evidence suggests that not all liability rules and related litigation procedures are created equal. Firms are systematically more likely to hold (firm-level patent stock) valid patents at the EPO when the liability and litigation rules are not complex and when the damage cap, broad statutory excuses, and reversed burden of proof are introduced.
Language:
English
Keywords:
medications
,
patents
,
administrative litigation
,
tort law
,
liability
,
litigation
,
propensity to patent
,
transaction costs
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
EF - School of Economics and Business
Publication status:
Published
Publication version:
Version of Record
Year:
2021
Number of pages:
18 str.
Numbering:
Vol. 11, iss. 2
PID:
20.500.12556/RUL-126684
UDC:
346
ISSN on article:
2158-2440
DOI:
10.1177/21582440211009470
COBISS.SI-ID:
25110019
Publication date in RUL:
04.05.2021
Views:
1451
Downloads:
295
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
SAGE open
Publisher:
SAGE
ISSN:
2158-2440
COBISS.SI-ID:
2586967
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
zdravila
,
patenti
,
upravni spor
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P5-0128
Name:
Izzivi vključujočega in trajnostnega razvoja v prevladujoči paradigmi ekonomskih in poslovnih znanosti
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back